Compare BLBD & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBD | AAPG |
|---|---|---|
| Founded | 1927 | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2013 | N/A |
| Metric | BLBD | AAPG |
|---|---|---|
| Price | $71.19 | $20.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $68.00 | $48.40 |
| AVG Volume (30 Days) | ★ 376.2K | 2.4K |
| Earning Date | 05-06-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.78 | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $1,480,099,000.00 | N/A |
| Revenue This Year | $5.87 | $290.34 |
| Revenue Next Year | $6.83 | N/A |
| P/E Ratio | $37.66 | ★ N/A |
| Revenue Growth | ★ 9.87 | N/A |
| 52 Week Low | $37.68 | $20.11 |
| 52 Week High | $81.51 | $48.45 |
| Indicator | BLBD | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 67.97 | 35.05 |
| Support Level | $51.63 | $20.11 |
| Resistance Level | N/A | $25.23 |
| Average True Range (ATR) | 2.93 | 0.49 |
| MACD | 0.58 | -0.22 |
| Stochastic Oscillator | 50.08 | 24.11 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.